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ABSTRACT 
Background: Rocuronium-induced neuromuscular block that spontaneously recovered to a 
train-of-four count of four can be reversed with sugammadex 0.5 or 1.0 mg/kg. We 
investigated if these doses of sugammadex can also reverse vecuronium at a similar level of 
block. 
Methods: Sixty-five patients were randomized and sixty-four were analyzed in this 
controlled, superiority study. Participants received general anesthesia with propofol, 
sevoflurane, fentanyl, and vecuronium. Measurement of neuromuscular function was 
performed with acceleromyography (TOF-Watch-SX®). Once the block recovered 
spontaneously to four twitches in response to train-of-four (TOF) stimulation patients were 
randomized to receive sugammadex 0.5, 1.0, 2.0 mg/kg, neostigmine 0.05 mg/kg or placebo. 
Time from study drug injection to normalized TOF ratio 0.9 and the incidence of incomplete 
reversal within 30 min were the primary outcome variables. Secondary outcome was the 
incidence of re-paralysis (normalized TOF ratio < 0.9). 
Results: Sugammadex, in doses of 1.0 and 2.0 mg/kg reversed a threshold TOF count of four 
to normalized TOF ratio ≥0.9 in all patients in 4.4 ± 2.3 min (mean±SD) and 2.6 ± 1.6 min, 
respectively. Sugammadex 0.5 mg/kg reversed the block in 6.8 ± 4.1 min in 70 % of patients 
(p<0.0001 vs. 1.0 and 2.0 mg/kg), whereas neostigmine produced reversal in 11.3 ± 9.7 min 
in 77% of patients (p>0.05 vs. sugammadex 0.5 mg/kg). The overall frequency of re-paralysis 
was 18.7% but this incidence varied from group to group.  
Conclusions: Sugammadex 1.0 mg/kg unlike 0.5 mg/kg properly reversed a threshold TOF 
count of four vecuronium-induced block, but did not prevent re-paralysis.  
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Like rocuronium, vecuronium is an aminosteroid neuromuscular blocking agent with 
intermediate duration of action
1
. Sugammadex is a modified ϒ-cyclodextrin compound 2 that 
reverses the neuromuscular blockade produced by rocuronium
3
, vecuronium
4 5 
and 
pipecuronium
6
 by encapsulating them, making them unavailable to interact with the nicotinic 
acetylcholine receptors at the neuromuscular junction. The encapsulation of steroidal 
relaxants by sugammadex is a one-to-one molecular interaction depending on the affinity of 
sugammadex for the relaxant
2
, on the depth of neuromuscular block at the time of antagonism 
and on the dose of sugammadex.
7
 The affinity of the neuromuscular blocking agent for 
sugammadex is numerically described by the association constant (Ka). The higher the Ka the 
greater the affinity. The Ka is 3.1 times higher for rocuronium than for vecuronium (1.79 x 
10
7
 mol/L and 5.72 x 10
6
 mol/L, respectively) 
8
, whereas the dissociation constant (Kd) which 
is the inverse of the association constant,  is 3.1 times higher for vecuronium than for 
rocuronium (0.17 and 0.055 µM, respectively).8 Several investigators compared the 
antagonism with sugammadex of moderate [train-of-four (TOF) count of two]
4  9
  and deep 
(post tetanic count 1 to 2) vecuronium- and rocuronium-induced neuromuscular block. 
10 11 12
 
Significant dose-response relationships were demonstrated for mean recovery times to TOF 
ratio 0.9 with sugammadex 0.5, 1.0, 2.0, 4.0 and 8.0 mg/kg showing slower recovery from 
vecuronium- (35 min vs. 1.7 min) than from rocuronium-induced neuromuscular block (16 
min vs. 1.1 min). 
9 10 
Also, recurrence of acceleromyographic neuromuscular block (TOF ratio 
< 0.9) was reported to occur in some patients that received low doses of sugammadex for the 
reversal of moderate or deep neuromuscular block. 
9 10 12
 However, the comparative literature 
on this topic is scant. For example, we do not know whether low dose sugammadex would 
properly reverse a shallow vecuronium-induced neuromuscular block and whether it would 
prevent a recurrent block. It has been demonstrated that a threshold TOF count of four 
rocuronium-induced neuromuscular block can be reversed with sugammadex 1.0 mg/kg 
within 2.1 min and sugammadex 0.5 mg/kg reversed such neuromuscular block in 4.1 min on 
average.
13
 These data, however, may not be valid for vecuronium. Since the neuromuscular 
potency of vecuronium is six times greater than that of rocuronium (ED95: 0.05 and 0.30 
mg/kg, respectively) 
1 
and their molecular weight is similar (637 and 610 Dalton, respectively, 
HTTP://WWW.SCBT.COM/DATASHEET-205880.HTML), fewer vecuronium than rocuronium 
molecules produce similar degrees of neuromuscular block. To encapsulate 1.0 mg 
vecuronium 3.4 mg of sugammadex is necessary, and to encapsulate the intubating dose (e.g. 
7 mg) 2.4 mg sugammadex is sufficient. Theoretically a sugammadex dose as low as 0.5 
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mg/kg is enough to encapsulate all vecuronium molecules present in the body at any time 
after the administration of vecuronium 0.10 mg/kg. Although the affinity of vecuronium for 
sugammadex is lower than that of rocuronium, we hypothesized that the above described 
factors may partially compensate the lower affinity of vecuronium and thus low doses of 
sugammadex would adequately reverse a threshold TOF count of four vecuronium induced 
neuromuscular block.  
 
METHODS 
Trial design and participants 
This single-center, randomized, controlled, five parallel-arm, superiority trial was approved 
by the local ethics committee at the University of Debrecen, Hungary and by the National 
Institute of Pharmaceutics, Budapest, Hungary: OGYI/3194-8/2014. The study is classified 
under EUDRACT number 2013-004666-34. 
The investigations and data collections were carried out at the University Hospital of 
Debrecen, Hungary, between April 2015 and May 2016. The study followed the CONSORT 
2010 recommendations for randomized controlled trials (www.consort-statement.org). 
Seventy patients undergoing routine elective surgery were assessed for eligibility and sixty 
five were enrolled in this study (Fig.1.). The study staff recruited the participants at the 
University Hospital of Debrecen, Hungary. Entrants gave written, informed consent to 
participate. They were randomly assigned to one of the 5 study groups to receive 
sugammadex 0.5, 1.0, 2.0 mg/kg or neostigmine 0.05 mg/kg and atropine 0.015 mg/kg or 
0.9% saline (placebo) (Fig 1). Inclusion criteria were age of 18 to 65 years, body mass index 
18.5 to 25 kg/m
2
, American Society of Anesthesiologists (ASA) physical status I to III, 
male/female 1:1, scheduled for elective surgery with an expected duration of at least 50 min 
necessitating muscle relaxant administration for intubation of the trachea, but not always full 
relaxation for surgery. Exclusion criteria were suspected difficult airway, bronchial asthma, 
chronic obstructive pulmonary disease, neuromuscular disease, suspected malignant 
hyperthermia, significant hepatic or renal dysfunction, glaucoma, allergy to the drugs used in 
this study, and taking medication known to alter the effect of neuromuscular blocking agents. 
Patients who participated in another study within 30 days were not included, nor were 
pregnant or breastfeeding women.  
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Interventions and neuromuscular monitoring 
Patients were given 7.5 mg midazolam orally 60 min before induction of anesthesia. In the 
operating room, an IV cannula was inserted in a forearm vein and vital signs monitoring was 
started. The patients then received prophylactic antibiotic in the form of cefazoline (2 g), 
cefotaxime (2.0 g) or metronidazole (500 mg) depending on the type of surgery. Anesthesia 
was induced with IV propofol (1.5 to 2.0 mg/kg) and fentanyl (2.0 µg/kg) and maintained 
with inhaled sevoflurane (1.5 to 1.8 vol%) in air-oxygen mixture supplemented with IV 
fentanyl according to clinical need. Patients’ lungs were manually ventilated with oxygen 
using a face mask until intubation of the trachea. Oxygen saturation was maintained above 
96%, normocapnia was ensured, esophageal temperature was maintained above 36°C using 
forced air warming system (Bair-Hugger® Arizant Healthcare Inc, Eden Prairie, MN). 
Neuromuscular monitoring was carried out using TOF-Watch-SX® acceleromyograph 
(Organon Teknika B.V., Boxtel, Holland). The adductor pollicis muscle contractions in 
response to ulnar nerve stimulation were recorded. The piezoelectric probe of the 
acceleromyograph was attached to the tip of the thumb. A hand adapter ensured preload of the 
thumb while making sure that it continued to return to its original position. The forearm and 
the fingers were immobilized and surface skin electrodes were placed over the ulnar nerve 
proximal to the wrist. A TOF mode of stimulation was started and repeated every 15 seconds 
for 3 minutes followed by a 5-second tetanic train of 50 Hz to stabilize the signal. Two 
minutes later automatic calibration was carried out (CAL-2 to set out supramaximal current 
intensity and to calibrate the device). TOF stimulation was recommenced delivering 
supramaximal square wave stimuli of 0.2 millisecond duration at 2 Hz frequency until the 
signal was stable. If the signal was not stable, the calibration was repeated. Data were 
recorded and stored on a computer using TOF-Watch-SX software version 2.2 INT (Organon 
Ireland Ltd. Dublin, Ireland). Skin temperature was measured at the forearm near the wrist 
and maintained above 32°C. Once the neuromuscular recording was stable vecuronium 0.10 
mg/kg (2 x ED95) was injected IV, and the trachea was intubated when the muscle response to 
TOF stimulation disappeared. If surgical relaxation was necessary, vecuronium 0.015 to 0.02 
mg/kg was administered when 1 to 2 twitches to TOF stimulation returned. The TOF 
stimulation was automatically delivered at every 15-seconds interval.  
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Reversal of a threshold TOF count of four block 
When four twitches in response to TOF stimulation reappeared at three consecutive TOF 
measurements (a threshold TOF count of four), a designated anesthesiologist injected the 
study drug upon the request of the attending anesthesiologist responsible for the patient and 
for the study, which was blinded to the injected study drug. The evolution of TOF ratio 
(T4/T1) and T1 amplitude (the first of 4 twitches to TOF stimulation) was followed online 
every15 seconds and was also recorded for later analysis. Once the displayed TOF ratio 
reached at least 1.0 (unchanged during 3 min), inhaled sevoflurane was discontinued and the 
trachea was extubated when the patients emerged from anesthesia. If normalized TOF ratio 
0.9 was not reached within 30 min after the study drug injection (time was agreed upon a 
priori to wait for recovery), incomplete reversal was considered and rescue reversal was given 
(rescue sugammadex 2.0 mg/kg). During this time period the patient’s trachea remained 
intubated. Adequate reversal was defined as average time of ≤ 5 min from the start of the 
study drug injection to normalized TOF ratio 0.9.  
Postoperative assessment of neuromuscular block 
After extubation of the trachea, patients were transferred to the recovery room. During the 
transport the nerve stimulator was set on standby mode and the forearm and hand adapter’s 
positioning was secured, and oxygen was administered by face mask. In the recovery room 
vital signs monitoring was continued and oxygen was delivered via a nasal cannula. A second 
designated anesthesiologist recommenced the acceleromyography without recalibration of the 
device (time zero). The measurements were repeated every 20 min for 60 minutes. At each 
point in time 3 consecutive TOF stimuli were delivered at 15-second intervals and their 
average value was considered. Postoperative recurrent neuromuscular block was defined as 
reappearance of normalized TOF ratios less than 0.9. Patients were surveyed for muscle 
weakness, force of coughing, ease to swallow and critical respiratory or circulatory events and 
would be immediately treated had such complications occurred. Supplementary oxygen 
administration, balloon-mask ventilation, equipment for intubation of the trachea and rescue 
sugammadex was available. After discharge from the recovery room, patients were observed 
by the study team for 24 hours to detect late adverse events. 
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Outcome measures 
Normalized TOF ratios of 0.9 were calculated and assessed as efficacy variables. 
Normalization was carried out by dividing the recorded values at recovery by baseline values 
before administration of vecuronium. 
14
  
Primary outcome measures of the study were: (i) the time from the start of the injection of the 
study drug to normalized TOF ratio of 0.9 characterized the effectiveness of reversal and (ii) 
the incidence of no recovery to normalized TOF ratio 0.9 within 30 min characterized the 
incomplete reversal.  
Secondary outcome measure of the study was the incidence of postoperative recurrent 
neuromuscular block in the recovery room during the first 60 min. 
Additional outcome measures were the times from study drug injection to recovery of T1 90%, 
to non normalized TOF ratio 1.0 and the number of patients reaching normalized TOF ratio 
1.0 
 
Sample size  
Calculation of sample size was carried out assuming that the usual time for recovery is 600 s 
with an SD of 200 s in patients treated with neostigmine and that sugammadex 0.5 mg/kg 
decreases the time of recovery to 300 s. Using a Type I error rate (α) of 0.05 10 subjects in the 
treatment groups would be needed to reach a power of 0.8. As we assumed that dropouts 
might occur, we included 13 patients in each group, bringing the total to 65 patients. 
 
Randomization and blinding 
The nature of randomization was 1:1 to obtain equal-sized study groups. The study statistician 
generated the randomization sequence using a web based online program (www. 
randomizer.org.).
 
The study staff enrolled participants. A designated anesthesiologist 
possessed the randomization code who assigned participants to intervention. She prepared the 
study drug and injected it at the request of the attending anesthesiologist. The size and color 
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of the syringes were similar to each other. Participants, the attending anesthesiologist and the 
anesthesiologist who performed the postoperative acceleromyographic measurements were 
blinded after assignment to interventions. 
 
Statistical analysis 
To analyze the primary outcome of time from the start of injection of the study drug to 
normalized TOF ratio of 0.9, we used one-way analysis of variance (ANOVA). We examined 
the assumptions of ANOVA using the Shapiro-Wilk W-test for the control of normal 
distribution of variables and the Levene-test to check the homogeneity of variances among the 
study groups. Because the assumptions of normality or homoscedasticity were not met by the 
data, we applied the Box-Cox transformation for evaluating the primary outcome variable. 
When variances differed even after transformation, we used the Welch F test for unequal 
variances. Post-hoc testing of differences among group means was based on Tukey’s HSD 
test. We also used ANOVA to analyze baseline variables (patient data and perioperative 
variables) when the assumptions of parametric tests were met by the data. Otherwise, we used 
the non-parametric Kruskal-Wallis ANOVA to compare groups. For comparing proportions, 
including the primary outcome measure of the incidence of incomplete reversals and the 
secondary outcome measure of the incidence of re-paralysis, we used the χ2 statistic. When 
the assumptions of the χ2 statistic were not met, we applied Cramer’s V statistic of 
association.  Because there were two components of the primary endpoint, we used α = 0.025 
(or half of the conventional α level of 0.05) to infer significance in analyses of outcome 
variables. We used α = 0.05 as a significance level in tests of baseline variables.  All statistical 
calculations were implemented in PAST 3.0.7
9
 or in R (version 3.2.2 R Development Team 
2015).
15 
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RESULTS 
Seventy patients were eligible, 65 agreed to participate in the trial. All enrolled patients were 
assigned to 1 of the 5 study groups. (Fig. 1). One patient in the sugammadex 1.0 mg/kg group 
was excluded from the study due to technical failure (broken acceleromyographic device) thus 
the data from 64 cases were analyzed.  The trial ended as anticipated, after the 24-hour-long 
observation period following the tracheal extubation of the last patient. 
There were no differences in sex, age, body mass index, control TOF ratio, control T1 (%), 
ASA physical status score or the duration of surgery among the five study groups (Table 1). 
There were no differences among groups in the dose of vecuronium and in the end-tidal 
sevoflurane concentrations at antagonism. There were likewise no differences among groups 
in the time intervals from last vecuronium injection to a threshold TOF count of four blocks 
(Table 2). 
Primary outcome  
Reversal with neostigmine took 11.3 min, significantly longer than reversal with sugammadex 
1.0 mg/kg (4.4 min) or 2.0 mg/kg (2.6 min) (Table 3, Tukey HSD test for both comparisons, p 
< 0.05), whereas the difference between neostigmine and 0.5 mg/kg sugammadex (6.8 min) 
was not statistically significant (p > 0.05) (Table 3). However, the variance in time to TOF 
ratio of 0.9 was significantly larger in the neostigmine group (94.1) than in the 0.5 mg/kg 
sugammadex group (16.6) (F = 5.671, p = 0.023). Within the sugammadex groups, there were 
significant differences in the times to normalized TOF ratio 0.9 because these times were 
shorter in the groups receiving sugammadex 1.0 or 2.0 mg/kg (4.4 min and 2.6 min, 
respectively) than in the sugammadex 0.5 mg/kg group (6.8 min) (Table 3; one-way ANOVA 
for the three sugammadex groups, F2,31 = 12.450, p = 0.0001, Tukey HSD tests, p < 0.05 for 
both comparisons). Calculations of the mean differences between pairs of study groups (Table 
4) confirmed these results, and additionally showed a significant difference between the 
sugammadex 1.0 mg/kg and 2.0 mg/kg groups (Tukey HSD test, p = 0.047). 
The number of incomplete reversals was 4 in the sugammadex 0.5 mg/kg group, 3 in the 
neostigmine group, 13 in the placebo group, and 0 in the sugammadex 1.0 and 2.0 mg/kg 
groups (Table 3). The difference in incomplete reversals between the placebo and the four 
treatment groups combined was significant (Fisher’s exact probability < 0.0001), whereas the 
difference between the sugammadex 0.5 mg/kg group and the neostigmine group was not 
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significant (Fisher’s exact p = 0.157). Calculations of odds ratios also confirmed the 
differences between the placebo and each of the four treatment groups (Table 4). All patients 
with incomplete reversal received rescue sugammadex 2.0 mg/kg and recovered to 
normalized TOF ratio 0.9 thereafter. These patients were not considered for the analysis of 
reversal times but were included in the assessment of the postoperative recurrent 
neuromuscular block.  
Secondary outcome 
Postoperative recurrent neuromuscular block occurred in 12 patients: 3 were in the 
sugammadex 0.5 mg/kg group, 4 in the sugammadex 1.0 mg/kg group, 2 in the sugammadex 
2.0 mg/kg group, 1 in the neostigmine group and 2 in the placebo group (Table 5). These 
proportions did not differ significantly among the groups (χ2 =2.708, df = 4, p = 0.608). 
Similarly, odds ratios pertaining to the occurrence of re-paralysis did not differ in either of the 
pairwise comparisons of study groups (Table 4). The within-patient variation between the 
three separated TOF measurements was analyzed in each of the 18 re-paralysis. The median 
coefficient of variation was 6.0% (IQR: 5.1%), while the geometric mean of the percentual 
coefficient of variation was 5.2. Precision of TOF measurement was deemed satisfactory if 
the discrepancy between repeated observations was within 2 times 5.2 
14
 (see additional web 
material 1.). Of the 12 patients with postoperative recurrent neuromuscular block four were 
asymptomatic (normalized TOF ratios 0.85, 0.87, 0.86, 0.89). Eight patients with TOF ratios 
0.85, 0.86, 0.83, 0.85, 0.86, 0.86, 0.74 and 0.72 complained about muscle weakness, which 
was associated with weakened coughing in 7, with positive head lift test in 4 and with 
difficulty swallowing in 4 cases. The duration of recurrent block was 40 min in one subject 
and 20 min in the others. The lowest TOF ratios were measured at 60 min, one in the 
sugammadex 2.0 mg/kg group (normalized TOF ratio 0.72) and one in the placebo group 
(normalized TOF ratio 0.74) after rescue sugammadex of 2.0 mg/kg. Both patients 
complained about muscle weakness, they had weakened coughing, difficulty swallowing, 
positive head lift test and difficulty in eye movement. Discharge of these patients from the 
recovery room was delayed by 20 to 30 min until they became asymptomatic.  
Additional outcome:  
The number of patients reaching normalized TOF ratio 1.0 was 2, 4, 5, 2 and 0 in the 
sugammadex 0.5, 1.0, 2.0 mg/kg, neostigmine and placebo groups, respectively. The times to 
reach non normalized TOF ratio 1.0 did not differ significantly from the times to reach 
11 
 
 
normalized TOF ratio 0.9. There was no difference among the treatment groups in times to 
achieve T1 90% (Table 3). 
Harms: No important harms or adverse effects were observed.  
 
DISCUSSION 
Summary of Results 
The current study investigated whether sugammadex 0.5 and 1.0 mg/kg adequately reverses a 
vecuronium induced neuromuscular block that spontaneously returned to a threshold TOF 
count of four. Criterion of adequate reversal was achievement of normalized TOF ratio 0.9 in 
≤ 5 min on average. Incomplete reversal was defined as failure to reach normalized TOF ratio 
0.9 within 30 min after administration of reversal agent. Also, the incidence of recurrent 
neuromuscular block (normalized TOF ratios < 0.9) was studied. Sugammadex 1.0 mg/kg 
adequately reversed the block in each patient, as did the standard dose (2.0 mg/kg). Of the 13 
patients that received sugammadex 0.5 mg/kg, 4 produced incomplete reversal. The mean 
reversal time for the remaining 9 patients was 6.8 min, thus did not fulfill the criterion of 
adequate reversal. Neostigmine was not significantly different from sugammadex 0.5 mg/kg 
with a mean reversal time of 11.3 min in 10 patients and with incomplete reversal in 3 cases. 
Recurrent block was detected in 12 patients. These results do not support our hypothesis that a 
threshold TOF count of four vecuronium-induced neuromuscular block can adequately be 
reversed with limited sugammadex doses similarly to a rocuronium induced block. 
13
 
There are two reasons to use a small-dose of sugammadex for reversal of residual 
neuromuscular block. The first is an economic one, attempting to decrease the costs required 
for sugammadex treatment.
13
 The second is that too much sugammadex on board would limit 
the options should re-intubation of the trachea or repeat surgery be needed shortly after the 
end of the case. 
16, 17 
However, the concept of reversal of residual neuromuscular block with 
clinically limited dose range of sugammadex generated concern about re-paralysis, arguing 
that sugammadex 1.0 mg/kg or 0.5 mg/kg is insufficient to restore the safety margin of the 
neuromuscular junction thus rebound of the block may happen.
18 19
 Actually only few studies 
have investigated the effect of low dose sugammadex on the reversal of shallow residual 
neuromuscular bocks.
20
 What we know about this topic is that 0.25 mg/kg of sugammadex is 
able to reverse a rocuronium induced block at a TOF ratio of 0.5 to 0.9 in an average time of 
12 
 
 
< 2 min 
7
 and that sugammadex 1.0 or 0.5 mg/kg adequately reversed a threshold TOF count 
of four rocuronium-induced block under sevoflurane anesthesia.
13
 Also moderate (T2) 
rocuronium- and vecuronium-induced neuromuscular blocks were successfully reversed under 
propofol-remifentanil anesthesia.
4
  
A multicentre study 
9
 demonstrated clear dose-response relationship for the reversal of 
moderate rocuronium- and vecuronium-induced neuromuscular block with sugammadex 0.5, 
1.0, 2.0 and 4.0 mg/kg under sevoflurane anesthesia. Recovery times to TOF ratio 0.9 were 
shorter in the rocuronium than in the vecuronium group, and the difference was the most 
pronounced at sugammadex 0.5 mg/kg. Recurrence of the block occurred in seven patients 
due to suboptimal doses of sugammadex, but also after the recommended dose of 2.0 mg/kg 
in one case. Duvaldestin et al.
10
 investigated the reversal of deep vecuronium and rocuronium 
induced neuromuscular block with increasing doses of sugammadex under sevoflurane 
maintenance anesthesia. Sugammadex in doses of ≥ 4.0 mg/kg provided rapid reversal of deep 
rocuronium- and vecuronium-induced neuromuscular block. Neuromuscular monitoring 
showed recurrence of neuromuscular block in 5 patients, all in the rocuronium group (2 
received 0.5 mg/kg and 3 received 1.0 mg/kg sugammadex). Eleveld et al. observed the 
rebound of neuromuscular block after attempting to reverse a deep rocuronium induced block 
with sugammadex 0.5 mg/kg.
12
 From these studies we know that low dose sugammadex is 
unsuitable to reverse moderate or deep rocuronium or vecuronium-induced neuromuscular 
block. 
What the present study adds to our knowledge is that sugammadex 0.5 mg/kg cannot reverse a 
threshold TOF count of four neuromuscular block to normalized TOF ratio 0.9 in 30% of the 
patients and it is not more effective than neostigmine in the remaining 70%. We confirmed 
that re-paralysis can occur even after the reversal of such neuromuscular block with 
sugammadex 2.0 mg/kg. Therefore caution is suggested when using limited clinical doses of 
sugammadex (≤ 2.0 mg/kg) for antagonism of vecuronium-induced residual block, and the 
use of quantitative neuromuscular monitoring is highly recommended. 
There may be several explanations of these results. Firstly, the complexation of relaxant-
sugammadex and its breakdown into constituent molecules depends on the propensity of the 
two substances to associate and to dissociate.
2
 Since sugammadex is more selective for 
rocuronium than for vecuronium [association constants (Ka) 1.79 x 10
7
 mol/L and 5.72 x 10
6
 
mol/L, respectively], 
8
 the complexation is slower with vecuronium than with rocuronium. 
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Secondly, as the dissociation constant of vecuronium is 0.17 µM, vs. 0.055 µM for 
rocuronium,
8
 higher relative sugammadex concentrations are required for complex formation 
with vecuronium than with rocuronium. This may explain why sugammadex 0.5 mg/kg was 
limited in reversing the residual effect of vecuronium, in contrast to what was previously 
found with rocuronium.
13
 Thirdly, the sugammadex/vecuronium concentration ratio, not the 
absolute number of vecuronium molecules in the body appears to be the decisive factor for the 
reversal of vecuronium block. Therefore, sugammadex 1.0 mg/kg and 2.0 mg/kg were 
effective while 0.5 mg/kg was not. Furthermore, none of the sugammadex doses administered 
in this study prevented the recurrence of neuromuscular block. The overall frequency of re-
paralysis was 18.7% but this incidence varied from group to group. This was an unexpected 
outcome, which raises the suspicion of artifacts due to displacement of the arm during the 
measurement of acceleromyographic TOF responses in patients recovering from anesthesia.
21
 
In order to prevent this bias, special care was taken by the study anesthesiologists to 
adequately fasten the arm during TOF stimulation, like in our previous study including 47 
awake patients that were monitored for residual neuromuscular blockade during 60 min in the 
recovery room.
22
 Since these patients presented neither clinical signs of residual paralysis nor 
TOF ratio depression, they can be considered as a control group for the current study and thus 
validating its results. With regard to the mechanism of re-paralysis, low doses of sugammadex 
may be sufficient for complex formation with the relaxant molecules in the central 
compartment, but are insufficient for redistribution from the periphery to the plasma. 
Furthermore, the dissociation of vecuronium from the complex over time (ref. Kd) also takes 
place and increases the possibility of rebounding block.
12
. Although it cannot be excluded 
with certitude, it is less likely that residual concentrations of sevoflurane enhanced the block 
in the postoperative period. It is also unlikely that the metabolite of vecuronium caused re-
paralysis; the doses were too small for this. No severe postoperative re-paralysis occurred in 
the patients, and the majority of recurrent blocks were “slight” (normalized TOF ratios 0.83 to 
0.89) apparently at the limit of the safety margin. 
Clinical signs of re-paralysis were observed in 8 patients without other adverse event. 
Nevertheless, recurrent neuromuscular block may be associated with postoperative 
complications such as hypoxia, weakness, pulmonary aspiration of gastric content and 
respiratory failure. The prevention of these complications may improve patients’ safety and 
decreases mortality rate.
23 
 
 
14 
 
 
 
Limitation of this study 
This study was based on acceleromyographic measurements of neuromuscular transmission, 
which is known to overestimate the recovery. However, we used preload and normalization to 
improve its accuracy.
14
 Had we considered non-normalized TOF ratios for postoperative 
recurrent neuromuscular block, five recurrent blocks would have been detected. We did not 
measure the plasma concentrations of sugammadex, vecuronium or 3-desacetylvecuronium, 
and spirometry was not carried out for the diagnosis of possible respiratory depression. 
Although the explanation of the result was based on published data, presumptions about the 
mechanism of reversal and postoperative recurrent neuromuscular block could not be avoided. 
Due to ethical reasons and tight operating schedules a 30 minutes cut off point in time was a 
priori included resulting in reduction of sample size in three treatment groups. Although the 
placebo control was excluded from the comparison of the reversal times, it allowed 
distinguishing the effect of sugammadex 0.5 mg/kg and neostigmine from spontaneous 
recovery. Of note, the administration of rescue treatment to placebo patients confirmed the 
occurrence of postoperative recurrent neuromuscular block after sugammadex 2.0 mg/kg. 
This issue is clinically relevant and therefore further studies are highly desirable to confirm 
these results. 
In conclusion, this study demonstrated, that sugammadex 0.5 mg/kg is insufficient to reliably 
guarantee prompt and satisfactory neuromuscular recovery following vecuronium 
administration at a threshold TOF count of four. Increasing the dose to 1.0 mg/kg adequately 
reversed this level of block, although recovery took twice as long as has been reported after 
rocuronium. In addition, recurrent neuromuscular block occurred in each treatment group. 
Sugammadex 0.5 mg/kg should not be used for the reversal of vecuronium-induced 
neuromuscular block and the use of quantitative neuromuscular monitoring is highly 
recommended.  
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Text to figure 1. Study flowchart.  
The administration of sugammadex, neostigmine and placebo was randomized and double 
blinded. The administration of vecuronium was open. nTOF 0.9= normalized TOF ratio 0.9. 
Light gray quadrangles: comparison for recovery times, dark gray quadrangles: excluded from 
comparison of recovery times, rescue sugammadex= 2 mg/kg. 
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Table 1. Comparison of baseline characteristics, duration of surgery and control acceleromyographic values. 
Variable 
‡
 Sugammadex 
0.5 mg/kg 
Sugammadex 
1.0 mg/kg 
Sugammadex 
2.0 mg/kg 
Neostigmine 
0.05 mg/kg 
Placebo 
0.9% saline 
p value 
Sex (M/F) 7/6 6/7 7/6 6/7 5/8 0.93 
#
 
Age (year) 47 ± 11.6 41 ± 10.1 48 ± 12.9 43 ± 12.4 48 ± 13.5 0.43 
##
 
BMI (kg/m
2
) 22.9 (21.5 - 24.1) 21.6 (20.1 - 23.8) 24.6 (21.6 - 25.1) 24.5 (21.1 - 24.9) 24.4 (23.2 - 24.9) 0.17 
###
 
Duration of surgery 
(min) 
75 (50 - 113) 45 (38 - 73) 80 (45 - 95) 60 (52.5 - 75) 60 (55 - 105) 0.34 
###
 
Control TOF ratio 1.07 (1.05 – 1.12) 1.10 (1.04 – 1.15) 1.07 (1.01 – 1.11) 1.07 (1.04 – 1.12) 1.06 (1.03 – 1.09) 0.77 
###
 
Control T1 % 96 ± 3.8 99 ± 5.0 98 ± 5.6 96 ± 6.8 100 ± 4.3 0.29 
##
 
ASA class (I/II/III) 3/10/0 5/8/0 4/9/0 6/7/0 4/9/0 0.77 
#
 
‡
 Means ± standard deviations are given when data met the assumptions of parametric statistical tests, otherwise, medians (interquartile ranges) 
are given. N = 13 in each group; 
#
 χ2-test, ## one-way ANOVA, ### Kruskal-Wallis ANOVA. 
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Table 2. Comparison of the study groups at antagonism. 
Variable 
‡
 
Sugammadex 
0.5 mg/kg 
Sugammadex 
1.0 mg/kg 
Sugammadex 
2.0 mg/kg 
Neostigmine 
0.05 mg/kg 
Placebo 
0.9% saline 
p value 
Total vecuronium dose 
(mg/kg) 
0.1 (0.10 - 0.12) 0.1 (0.10 - 0.10) 0.1 (0.10 - 0.11) 0.1 (0.10 - 0.11) 0.1 (0.10 - 0.11) 0.44 
#
 
Sevoflurane concentration 
(vol%) 
1.5 (1.3 - 1.9) 1.8 (0.9 - 2.1) 1.6 (1.1 - 2.0) 1.8 (1.4 - 1.9) 1.7 (1.4 - 1.8) 0.99 
#
 
Time from last vecuronium 
dose to antagonism (min) 
53 ± 26 68 ± 33 49 ± 14 50 ± 19 54 ± 23 0.25 ## 
Normalized TOF ratio  
0.10 (0.07 –
0.11) [11] 
0.09 (0.07 –
0.11) [11] 
0.10 (0.10 – 
0.14) [12] 
0.09 (0.08 –
0.13) [12]  
0.09 (0.07 –
0.11) [12] 
0.76 
#
 
Normalized T1 (%) 32 ± 11 31 ± 13 33 ± 10 34 ± 13 31 ± 9 0.94 
##
 
‡
 Means ± standard deviations are given when data met the assumptions of parametric statistical tests, otherwise, medians (interquartile ranges) 
are given. Sample size is 13, except where indicated in brackets; 
#
 Kruskal-Wallis ANOVA, 
##
 one-way ANOVA. 
 
  
20 
 
 
Table 3. Primary outcome of the study. 
Variable 
‡
 Sugammadex 
0.5 mg/kg 
Sugammadex 
1.0 mg/kg 
Sugammadex 
2.0 mg/kg 
Neostigmine 
0.05 mg/kg 
Placebo 
0.9% saline 
p value 
Incomplete recovery (N) 4 [13] 0 [12] 0 [13] 3 [13] 13 [13] < 0.0001 
#
 
Time to normalized TOF  
ratio 0.9 (min) 
6.8 ± 4.1 [9]ab 4.4 ± 2.3 [12]bc 2.6 ± 1.6 [13]c 11.3 ± 9.7 [10]a incomplete 
recovery 
< 0.0001 
##
 
Time to T1 90% (min) 4.5 ± 3.1 [10] 3.0 ± 2.2 [10] 3.6 ± 4.5 [9] 2.9 ± 1.6 [6] 15.3 ± 6.7 [2] 0.21 
##
 
Time to non-normalized 
TOF ratio of 1.0 (min) 
8.4 ± 5.8 [8]ab 4.5 ± 2.3 [12]bc 5.1 ± 6.2 [13]c 12.8 ± 9.1 [10]a incomplete 
recovery 
< 0.0001 
##
 
‡
 Means ± standard deviations are given for time variables. Group means not sharing superscript letters differ significantly (Tukey’s HSD test, p 
< 0.05). Sample sizes are given in brackets; 
#
 Cramer’s V, ## one-way ANOVA. 
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Table 4. Estimates of the mean differences (and their 95% confidence intervals) in the time from injection of the study drug to normalized TOF 
ratio of 0.9 between pairs of study groups, and odds ratios for the number of failed reversals at 30 min and the number of patients with post-
operative recurrent neuromuscular block (PORNB) between pairs of study groups. For example, the time to normalized TOF ratio of 0.9 was on 
average 2.5 min shorter in the Sugammadex 1.0 mg/kg group than in the Sugammadex 0.5 mg/kg group. 
Variable 
‡
 Study group Sugammadex 
1.0 mg/kg 
Sugammadex 
2.0 mg/kg 
Neostigmine 
0.05 mg/kg 
Placebo 
0.9% saline 
Time to normalized 
TOF ratio of 0.9 
Sugammadex 0.5 mg/kg -2.5 (-8.6, 3.6) -4.2 (-10.2, 1.8)** 4.4 (-1.9, 10.8) – 
Sugammadex 1.0 mg/kg – -1.7 (-7.3, 3.8)* 6.9 (1.0, 12.8)* – 
Sugammadex 2.0 mg/kg 
 
– 8.6 (2.8, 14.4)*** – 
Number of incomplete 
reversals at 30 min 
Sugammadex 0.5 mg/kg 11.84 (0.57, 247.85) 12.79 (0.61, 266.67) 1.48 (0.26, 8.50) 0.018 (0.00, 0.37)** 
Sugammadex 1.0 mg/kg − 1.08 (0.02, 58.66) 0.12 (0.01, 2.60) 0.002 (0.00, 0.08)** 
Sugammadex 2.0 mg/kg 
 
− 0.11 (0.01, 2.40) 0.001 (0.00, 0.07)** 
Neostigmine 0.05 mg/kg 
  
− 0.012 (0.00, 0.27)** 
Number of patients 
with recurrent block 
Sugammadex 0.5 mg/kg 0.67 (0.11, 3.93) 1.67 (0.23, 12.35) 4.00 (0.36, 45.10) 1.833 (0.25, 13.47) 
Sugammadex 1.0 mg/kg − 2.50 (0.36, 17.3) 6.00 (0.56, 63.99) 2.750 (0.40, 18.88) 
Sugammadex 2.0 mg/kg 
 
− 2.40 (0.19, 30.52) 1.100 (0.13, 9.34) 
Neostigmine 0.05 mg/kg 
  
− 0.458 (0.04, 5.79) 
‡
 Estimates (95% confidence intervals) of the mean differences between study groups are given for Time to normalized TOF ratio of 0.9, and 
odds ratios (95% confidence intervals) are given for number of failed reversals and number of patients with reparalysis. Tukey HSD test; * p < 
0.05, ** p < 0.01, *** p < 0.001. 
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Table 5.  Secondary outcome of the study: incidence of postoperative re-paralysis during the first 60 min in the recovery room.  
Variable 
‡
 Measure 
Sugammadex 
0.5 mg/kg 
Sugammadex 
1.0 mg/kg 
Sugammadex 
2.0 mg/kg 
Neostigmine 
0.05 mg/kg 
Placebo 
0.9% saline 
#Time from extubation to first 
TOF measurement (min)      
Median (IQR) 
23.2 (19.8 - 28.2) 24.5 (21.0 - 27.2) [12] 23.3 (16.0 - 30.8) 24.9 (18.8 - 35.9) 21.9 (16.5 - 26.8) 
Normalized TOF 
ratios at 0 min 
Mean ± SD 
95% CI 
Median 
(range) 
1.01 ± 0.09 
0.96-1.06 
0.99 (0.85-1.27) 
0.96 ± 0.09 
0.91-1.01 
0.95 (0.83-1.11) 
1.01 ± 0.08 
0.97-1.06 
1.02 (0.85-1.19) 
1.05 ± 0.09 
1.00-1.10 
1.04 (0.95-1.33) 
1.01 ± 0.05 
0.98-1.03 
1.00 (0.96-1.10) 
Normalized TOF 
ratios at 20 min 
Mean ± SD 
95% CI 
Median 
(range) 
1.04 ± 0.15 
0.96-1.12 
1.03 (0.84-1.42) 
1.01 ± 0.09 
0.96-1.06 
1.01 (0.85-1.15) 
1.01 ± 0.05 
0.98-1.04 
1.02 (0.92-1.10) 
1.04 ± 0.10 
0.98-1.09 
1.01 (0.86-1.28) 
1.00 ± 0.06 
0.96-1.03 
1.01 (0.89-1.11) 
Normalized TOF 
ratios at 40 min 
Mean ± SD 
95% CI 
Median 
(range) 
0.99 ± 0.08  
0.95-1.04 
1.01 (0.86-1.14) 
0.98 ± 0.07 
0.94-1.02 
0.97 (0.87-1.09) 
1.01 ± 0.06 
0.98-1.04 
1.02 (0.92-1.08) 
1.04 ± 0.07 
1.00-1.08 
1.04 (0.96-1.17) 
1.03 ± 0.08 
0.98-1.07 
1.02 (0.86-1.16) 
1.04 ± 0.12 
Normalized TOF 
ratios at 60 min 
Mean ± SD 
95% CI 
Median 
(range) 
1.04 ± 0.13 
0.97-1.12 
0.99 (0.91-1.32) 
0.99 ± 0.08 
0.95-1.04 
1.00 (0.86-1.13) 
1.00 ± 0.13  
0.93-1.08 
0.99 (0.72-1.26) 
1.03 ± 0.07 
0.99-1.06 
1.03 (0.91-1.12) 
1.05 (0.74-1.31) 
Recurrent block Yes /No 3/9 4/8 2/10 1/12 2/11 
Medians (interquartile ranges) are given for time between the last train-of-four (TOF) measurement in the operating room and the first TOF 
measurement in the recovery room (time 0 min). Means ± standard deviations and medians (range) of normalized TOF ratios at four points in 
time in the recovery room are given. The number of patients with and (without) post-operative recurrent neuromuscular block in the study 
groups. #Kruskal-Wallis H = 2.611, p = 0.625. 
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ADDITIONAL WEB MATERIAL 
Variation of acceleromyographic TOF ratios during measurements in the recovery 
room. 
Twelve patients had recurrent neuromuscular block (normalized average TOF ratio < 0.9) on 
18 occasions (bold italic fonts). Three normalized TOF ratios are reported for each patient on 
each occasion. Each table shows data obtained at different measurement times (0, 20, 40, 60 
min).  The coefficients of variation of TOF ratios have been calculated for each patient. The 
median coefficient of variation for the dataset was 6% (IQR: 5.1). 
 
Table 1. Time 0 
Patients  Study group 
TOFR 
1 
TOFR 
2 
TOFR 
3  
Mean TOFR 
Coefficient of 
variation 
34 sug  0,5 mg /kg 0.86 0.83 0.88 0,85      0.02 
36 
    sug  1.0 
mg/kg    
0.87 
0.88 0.88 0,88      0.006 
44 sug 1.0 mg/kg   0.86 0.86 0.78 0,83      0.05 
62 sug 1.0 mg/kg   0.90 0.84 0.85 0,86      0.037 
55 sug 2.0 mg/kg   0.87 0.87 0.87 0,87      0 
sug:=sugammadex, TOFR=train-of-four ratio 
 
Table 2. 20 min 
Patients Study group 
TOFR 
1 
TOFR 
2 
TOFR 
3 
Mean TOFR 
Coefficient of 
variation 
18     placebo      1.0 0.78 0.88 0,88       0.068 
37     neostigmine 0.93 0.80 0.85 0,86       0.076 
10 sug 0,5 mg /kg 1.21 0.81 0.61 0,87       0.34 
34 sug 0,5 mg /kg 0.78 0.85 0.90 0,84       0.07 
60 sug 0,5 mg /kg  0.91 0.88 0.88 0,89       0.02 
11     sug 1.0 mg/kg  0.88 0.79 0.89 0,85       0.06 
sug: sugammadex, TOFR=train-of-four ratio 
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Table 3. 40 min 
Patients Study group 
TOFR 
1 
TOFR 
2 
TOFR 
3 
Mean TOFR 
Coefficient of 
variation 
7   placebo 0.82 0.88 0.87 0,85       0.06 
34   sug 0,5 mg /kg  0.86 0.85 0.88 0,86       0.017 
62   sug 1.0 mg/kg  0.81 0.90 0.90 0,87       0.06 
sug: sugammadex, TOFR=train-of-four ratio 
 
 
 
Table 4. 60 min 
Patients Study group 
TOFR 
1 
TOFR 
2 
TOFR 
3 
Mean TOFR 
Coefficient of 
variation 
7    placebo 0.70 0.73 0.80 0,74        0.07 
44   sug 1.0 mg/kg  0.96 0.85 0.78 0,86        0.105 
62   sug 1.0 mg/kg  0.82 0.88 0.91 0,87        0.05 
3   sug 2.0 mg/kg  0.81 0.64 0.71 0,72        0.13 
sug: sugammadex, TOFR=train-of-four ratio 
 
 
